Multiple sclerosis News, Reviews & Resources- Page 2 of 2 - Labiotech.eu

Home Multiple sclerosis Page 2

Latest Posts

Apitope Multiple Sclerosis ATX MS 1467 phase IIa 1

News and Trends 21 Feb 2017

A New Peptide Vaccine for Multiple Sclerosis Succeeds in Phase IIa

Apitope is developing therapeutic peptides to induce suppression of autoimmune responses towards self-antigens. Their recent phase IIa trial has revealed…

February 21, 2017 - 3 minutesmins - By Melanie De Almeida

shutterstock 562105219

News and Trends 30 Jan 2017

‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier

Ossianix, partnered with Lundbeck, is developing shark antibodies that can help therapeutics cross the blood brain barrier. Ossianix develops shark-inspired…

January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 546920338

News and Trends 26 Jan 2017

Europe’s Largest Biotech Actelion Seals the Deal with J&J for €28B

Actelion will be acquired by J&J for a whopping €27.9B, and its early R&D pipeline will be spun out into…

January 26, 2017 - 2 minutesmins - By Evelyn Warner

shutterstock 217051729

News and Trends 2 Jan 2017

An EU Project will tackle Multiple Sclerosis using Personalized Multi Omics

The MultipleMS Consortium has been granted €15M by the EU Horizon 2020 to improve the treatment of multiple sclerosis using personalized…

January 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT

shutterstock 162816629

News and Trends 24 Oct 2016

Here comes the First-ever Combination Therapy for Multiple Sclerosis

Actelion is overcoming the upcoming expiration of one of its most profitable patents and it's using its strong position to…

October 24, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Sep 2016

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

GeNeuro is developing a unique treatment for multiple sclerosis. We interviewed Miguel Payro, the company's CFO, who explained its advantageous position against big…

September 30, 2016 - 1 minutemin - By Clara Rodríguez Fernández

21086425615 12170e7df2 o

News and Trends 20 Sep 2016

UPDATE: Novartis is Favoured to Win the Race for a New MS Drug

Novartis is poised to kick off the next generation of multiple sclerosis treatments after siponimod performs well in Phase III. The…

September 20, 2016 - 2 minutesmins - By Evelyn Warner

multiple sclerosis by decade3d anatomy online FI

News and Trends 15 Sep 2016

Roche’s New Antibody is besting the best MS Drug

Roche is poised to blow away the competition for the new multiple sclerosis drug with its leading candidate, Ocrevus (ocrelizumab).…

September 15, 2016 - 2 minutesmins - By Evelyn Warner

geneuro euronext multiple sclerosis biotech

News and Trends 16 Apr 2016

First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!

We last wrote about GeNeuro in January, when they announced the launch of an IPO for their Multiple Sclerosis phase…

April 16, 2016 - 2 minutesmins - By Dani Bancroft

medday multiple sclerosis neurodegenerative disease md1003

News and Trends 11 Apr 2016

French Biotech gets €34M to bring Multiple Sclerosis Drug to the US

MedDay (France) has raised €34M that should help pay a US phase III for its leading candidate for Multiple Sclerosis - as…

April 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

sanofi genzyme biotech finance 4bn

News and Trends 11 Feb 2016

Sanofi-Genzyme: Still successful 5 years after the acquisition?

Back in 2011, France's biggest Pharmaceutical company Sanofi decided to purchase Genzyme Corp. for more than $20 billion, thus becoming…

February 11, 2016 - 3 minutesmins - By Dani Bancroft

Apitope wales

News and Trends 30 Sep 2015

Apitope relocates to Wales after €12M series B financing round

Now, as we've recently discussed here at Labiotech, there doesn't appear to be many Welsh biotechs...however, this is all about…

September 30, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 24 Aug 2015

Novartis signs $1Bn deal for GSK’s Multiple Sclerosis Antibody

Is this Novartis' next blockbuster? The Swiss company has acquired GlaxoSmithKline's (GSK) immunosuppressive antibody Ofatumumab for up to $1Bn. The…

August 24, 2015 - 2 minutesmins - By Philip Hemme

mapi pharma GA depot2

News and Trends 1 Jun 2015

After two failed IPOs, Mapi Pharma raised €9 Million from private investors

Private investors have finally backed Mapi Pharma’s project with €9.1M. Shavit Capital has led the Series A financing round to…

June 1, 2015 - 2 minutesmins - By Lourdes Riquelme

Genzyme

News and Trends 22 May 2015

Genzyme joins the never-ending list of Ablynx’ partners

Genzyme is joining Ablynx' partner list, which already includes AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis.…

May 22, 2015 - 2 minutesmins - By Joachim Eeckhout

Alzheimer Alkermes

News and Trends 4 Mar 2015

Alkermes presents its new treatment of Alzheimer’s agitation

Alkermes reveals a new drug candidate, ALKS 7119, for treatment of Alzheimer’s agitation, depression and other central nervous system (CNS)…

March 4, 2015 - 2 minutesmins - By Lourdes Riquelme

ADVERTISEMENT

Ipsen Canbex

News and Trends 25 Feb 2015

Ipsen buys an option to Acquire Canbex

Canbex, a spin-off of University College London (UCL) that raised a Series A financing of €2.8M in 2013 from MS…

February 25, 2015 - 2 minutesmins - By Lourdes Riquelme

article geneuro servier

News and Trends 15 Dec 2014

Will there be a New Merck-Serono?

GeNeuro SA has signed a unique partnership with Servier. The French pharmaceutical giant have bought an option for €38M on…

December 15, 2014 - 2 minutesmins - By Julie Lellouche

Forward Pharma

News and Trends 20 Aug 2014

Danish biotech Forward Pharma files for $200m IPO

Forward Pharma, a biopharmaceutical company focused on a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis, today…

August 20, 2014 - 1 minutemin - By Joachim Eeckhout

Active Biotech

News and Trends 15 Aug 2014

Active Biotech and Teva together in a Phase II clinical trial against Huntington’s disease

Active Biotech announced today that its partner Teva Pharmaceutical will initiate a phase II clinical trial to evaluate the efficacy…

August 15, 2014 - 1 minutemin - By Joachim Eeckhout